Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
Authors:
- Leif BjermerLBLeif Bjermer
- Job F. M. van BovenJBJob F. M. van Boven
- Madlaina Costa-ScharplatzMCMadlaina Costa-Scharplatz
- Dorothy L. KeiningerDKDorothy L. Keininger
- Florian S. GutzwillerFGFlorian S. Gutzwiller
- Karin LisspersKLKarin Lisspers
- Ronan MahonRMRonan Mahon
- Petter OlssonPOPetter Olsson
- Nicolas RocheNRNicolas Roche
Open Access
- 11 December 2017
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 18 (1) , 206
Abstract
This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer’s perspective and were discounted at 3% annually. Uncertainty in model input values was studied through one-way and probabilistic sensitivity analyses. Subgroup analyses were also performed. IND/GLY was associated with lower costs and better outcomes compared with SFC over all the analysed time horizons. Use of IND/GLY resulted in additional 0.192 LYs and 0.134 QALYs with cost savings of €1211 compared with SFC over lifetime. The net monetary benefit (NMB) was estimated to be €8560 based on a willingness-to-pay threshold of €55,000/QALY. The NMB was higher in the following subgroups: severe (GOLD 3), high risk and more symptoms (GOLD D), females, and current smokers. IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year.Keywords
Funding Information
- Novartis Pharma AG (Switzerland)
This publication has 22 references indexed in Scilit:
- Health economic costs of COPD in Sweden by disease severity – Has it changed during a ten years period?Respiratory Medicine, 2013
- Inhaled corticosteroids in COPD and the risk of serious pneumoniaThorax, 2013
- Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyThe Lancet Respiratory Medicine, 2013
- Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic ModellingPharmacoEconomics, 2013
- Risk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrimary Care Respiratory Journal, 2012
- Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2012
- Up-to-date on mortality in COPD - report from the OLIN COPD studyBMC Pulmonary Medicine, 2012
- The prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden – the Burden of Obstructive Lung Disease (BOLD) study: cross‐sectional population‐based studyThe Clinical Respiratory Journal, 2011
- Exacerbations of Chronic Obstructive Pulmonary DiseaseProceedings of the American Thoracic Society, 2007
- Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?Chest, 2006